GenVec, Inc. (GNVC)
(Real Time Quote from BATS)
$7.12 USD
-0.02 (-0.24%)
Updated Jun 15, 2017 03:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[GNVC]
Reports for Purchase
Showing records 1 - 20 ( 79 total )
Industry: Medical - Biomedical and Genetics
ValuEngine Detailed Valuation Report for GNVC
Provider: ValuEngine, Inc
Industry: Medical - Biomedical and Genetics
Intrexon Acquires GenVec; Terminating Coverage
Provider: Rodman & Renshaw, Co.
Industry: Medical - Biomedical and Genetics
Intrexon Acquires GenVec; Terminating Coverage
Provider: H.C. Wainwright & Co., Inc.
Industry: Medical - Biomedical and Genetics
Intrexon Acquiring GenVec for $7 per Share; Downgrading to Neutral and Lowering Target to $7
Provider: Rodman & Renshaw, Co.
Industry: Medical - Biomedical and Genetics
Intrexon Acquiring GenVec for $7 per Share; Downgrading to Neutral and Lowering Target to $7
Provider: H.C. Wainwright & Co., Inc.
Industry: Medical - Biomedical and Genetics
We are dropping coverage due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
Novartis CGF166 Program Active; 1-for-10 Reverse Split Effected
Provider: H.C. Wainwright & Co., Inc.
Industry: Medical - Biomedical and Genetics
Novartis CGF166 Program Active; 1-for-10 Reverse Split Effected
Provider: Rodman & Renshaw, Co.
Industry: Medical - Biomedical and Genetics
ROTH Healthcare Monthly - Longing for Better Blood at ASH
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
3Q16 Results; We Should "Hear" Something in 2017
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Healthcare: Inaugural Healthcare Monthly; Catalysts Galore
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
2Q16 Financial Results; Hearing Loss Trial Underway; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Industry: Medical - Biomedical and Genetics
2Q16 Financial Results; Hearing Loss Trial Underway; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Industry: Medical - Biomedical and Genetics
2Q16 Results; Model Update; Waiting to "Hear" From NVS and Platform
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
FDA Lifts Clinical Hold on CGF166; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Industry: Medical - Biomedical and Genetics
FDA Lifts Clinical Hold on CGF166; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Industry: Medical - Biomedical and Genetics
Lead Value Driver, CGF166, Back in Play; Target Adjusted to $2
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Assuming Coverage with Buy and $2.30 Price Target
Provider: Rodman & Renshaw, Co.